ASCL1 and breast cancer: Importantly, the inhibition of ASCL1 significantly increased paclitaxel sensitivity both in vitro and in vivo, aligning with the bioinformatics data and suggesting that targeting ASCL1 could improve therapeutic outcomes in BC.